Quantitative 3-T multi-parametric MRI and step-section pathology of recurrent prostate cancer patients after radiation therapy

Catarina Dinis Fernandes¹ · Ghazaleh Ghobadi¹ · Henk G. van der Poel² · Jeroen de Jong³ · Stijn W. T. P. Heijmink⁴ · Ivo Schoots⁴ · Iris Walraven¹ · Petra J. van Houdt¹ · Milena Smolic¹ · Floris J. Pos¹ · Uulke A. van der Heide¹

Received: 12 July 2018 / Revised: 30 August 2018 / Accepted: 2 October 2018 / Published online: 12 November 2018
© The Author(s) 2018

Abstract
Objectives Diagnosis of radio-recurrent prostate cancer using multi-parametric MRI (mp-MRI) can be challenging due to the presence of radiation effects. We aim to characterize imaging of prostate tissue after radiation therapy (RT), using histopathology as ground truth, and to investigate the visibility of tumor lesions on mp-MRI.

Methods Tumor delineated histopathology slides from salvage radical prostatectomy patients, primarily treated with RT, were registered to MRI. Median T2-weighted, ADC, $K_{\text{trans}}$, and $k_{\text{ep}}$ values in tumor and other regions were calculated. Two radiologists independently performed mp-MRI-based tumor delineations which were compared with the true pathological extent. General linear mixed-effect modeling was used to establish the contribution of each imaging modality and combinations thereof in distinguishing tumor and benign voxels.

Results Nineteen of the 21 included patients had tumor in the available histopathology slides. Recurrence was predominantly multifocal with large tumor foci seen after external beam radiotherapy, whereas these were small and sparse after low-dose-rate brachytherapy. MRI-based delineations missed small foci and slightly underestimated tumor extent. The combination of T2-weighted, ADC, $K_{\text{trans}}$, and $k_{\text{ep}}$ had the best performance in distinguishing tumor and benign voxels.

Conclusions Using high-resolution histopathology delineations, the real tumor extent and size were found to be underestimated on MRI. mp-MRI obtained the best performance in identifying tumor voxels. Appropriate margins around the visible tumor-suspected region should be included when designing focal salvage strategies. Recurrent tumor delineation guidelines are warranted.

Key Points
• Compared to the use of individual sequences, multi-parametric MRI obtained the best performance in distinguishing recurrent tumor from benign voxels.
• Delineations based on mp-MRI miss smaller foci and slightly underestimate tumor volume of local recurrent prostate cancer.
• Focal salvage strategies should include appropriate margins around the visible tumor.

Keywords Prostate Cancer · Local neoplasm recurrence · Magnetic resonance imaging · Pathology · Radiotherapy

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00330-018-5819-y) contains supplementary material, which is available to authorized users.
Abbreviations

ADC  Apparent diffusion coefficient  
CG   Central gland  
DCE-MRI Dynamic contrast-enhanced MRI  
DWI-MRI Diffusion-weighted imaging MRI  
EBRT External beam radiotherapy  
$k_{\text{trans}}$ Rate of contrast agent transfer from vascular space to extravascular and extracellular space  
$k_{\text{ep}}$ Rate constant from extravascular and extracellular space to vascular space  
MRI Magnetic resonance imaging  
mp-MRI Multi-parametric MRI  
PCa Prostate cancer  
PET Positron emission therapy  
PSA Prostate-specific antigen  
PU Periurethra  
PZ Peripheral zone  
RT Radiation therapy  
SRP Salvage radical prostatectomy

Introduction

Depending on the risk group, 5-year disease-free survival varies from 67 to 80% for prostate cancer patients who are treated with whole-gland radiation therapy (RT) to 78 Gy [1]. Most patients with recurrent disease have developed metastasis, yet a small but significant proportion will harbor locally recurrent disease only [2, 3]. For these patients, salvage treatment options include radical prostatectomy, brachytherapy, cryotherapy, or high-intensity focused ultrasound [4]. Whole-gland approaches, such as salvage radical prostatectomy (SRP), are reported to obtain good disease control, however with a high chance of severe gastrointestinal and genitourinary complications when compared with radical prostatectomy in primary disease [5].

Focal salvage strategies aim at reducing these comorbidities by sparing the uninvolved tissue while specifically targeting recurrent cancer. When evaluated in radio-recurrent PCa, the complications of focal approaches are comparable or lower than in whole-gland strategies, with a 5-year biochemical disease-free survival of 46.5–54.5% [4]. Successful development of focal salvage strategies for local recurrent PCa requires an accurate detection and localization of the tumor. Positron emission tomography (PET) with 68Ga PSMA ligands offers high sensitivity to detect recurrent PCa [6], yet the poor spatial resolution limits its use for focal salvage strategies. Magnetic resonance imaging (MRI) alongside PET is the most used modality for recurrence diagnosis. High-resolution anatomical and functional imaging makes MRI attractive for the preparation of focal salvage treatments [7].

Materials and methods

Patients

Twenty-one patients with radio-recurrent PCa, who underwent mp-MRI for local staging prior to SRP between 2011 and 2017, were retrospectively included. Biochemical recurrence was established according to the Phoenix criteria [13]. All patients had biopsy-proved recurrence and absence of distant metastasis on choline PET scans. External beam radiotherapy (EBRT)- and low-dose rate (LDR) brachytherapy-treated patients were included.

MRI acquisition

Patients were scanned on a 3T Achieva (16), Achieva dStream (3), or Ingenia (2) MRI scanner (Philips Healthcare) between June 2011 and March 2017. Thirteen patients were scanned using an endorectal coil in addition to a torso or cardiac phased array coil. The mp-MRI protocol included triplanar T2w turbo spin-echo (TE 90–130 ms, TR > 2600 ms) and axial T1w-weighted (T1w) gradient echo sequences (TE < 2.3 ms, TR < 5.3 ms). DWI was acquired using a single-shot spin-echo echo-planar imaging sequence (b-values between 100 and 1000s/mm²), from which apparent diffusion coefficient (ADC) maps were generated. DCE was acquired with a 3D T1w spoiled gradient echo sequence (TE/TR 2/4 ms),
dynamic interval 2.3–2.9 s over 5–6 min, with intravenous administration of 7.5 mmol gadoteric acid (Dotarem). For seven patients, the DCE sequence was not acquired. The pharmacokinetic parameter maps $K^{\text{trans}}$ and $k_{\text{ep}}$ were derived from the DCE scans. A balanced steady-state free precession (bSSFP) sequence was acquired for fiducial and seed visualization in seven patients. MRI acquisition and post-processing details can be found in the Supplementary materials.

Visual inspection was used to assess displacements between the functional sequences and the T2w scans, with rigid registration performed when necessary. The T2w voxel size in plane resolution was between 0.3 and 0.8 mm, with a slice thickness of 3 mm. All maps were resampled to the T2w grid.

**Pathology**

Whole-mount axial slides, stained with hematoxylin and eosin (H&E), were used for histopathological validation. Slides at the apex and base of the specimen were sliced parasagittally for extra-prostatic extension evaluation and were excluded from analysis. The slides were digitalized using an Aperio ScanScope XT (Aperio Technologies). Supervised by an uro-pathologist (6 years of experience), tumor delineations were made (resolution 0.5 μm/pixel) on the digitized slides using ImageScope.

**T2w MRI and H&E registration**

The registration between H&E slides and the transversal T2w MRI was performed by two observers in consensus. A T2w slice was visually assigned to each H&E slide. Slide matching was performed considering the order of the slides, the location of the apex and base of the prostate, visible anatomical landmarks, and the relative size and shape of subsequent H&E and T2w slices. Each H&E slide was then registered to its matched T2w slice using deformable registration based on landmark points (Coherent Point Drift) [14] implemented in MATLAB R2015a (The MathWorks). Landmark points included the urethra, nodules, the prostate boundary, and the tumor.

The registration error was estimated by selecting one landmark per pathology slide and measuring the Euclidean distance between the point in the T2w and in the registered pathology.

After registration, tumor delineations on the H&E slides were propagated to MRI. To ensure that only tumor voxels were used to characterize imaging and train the mixed model, tumor delineations were eroded in all directions by 1 mm.

All further analyses were restricted to the MRI slices for which a matching H&E slide existed.

**Region of interest segmentation**

A ROI was delineated in the levator ani muscle and the median SI in this region was used to normalize the T2w images. For MRI slices with H&E match, the entire prostate and peripherial zone (PZ) were delineated using the transversal T2w MRI. The central gland (CG) was defined as the remaining non-PZ region, comprising the central and transition zone. The periurethral (PU) region was delineated with both sagittal and transversal T2w MRI. All voxels within these regions were included in the analysis. The location of implanted seeds and fiducial markers, as visible in the T1w or bSSFP sequences, was removed from the analyses.

Two uro-radiologists (14 and 7 years of experience) independently delineated suspected tumor regions, having access to mp-MRI and the radiological report, the PET choline scans, and the biopsy results. Since PI-RADS v2 [15] is not applicable to recurrent prostate cancer, tumor was defined as a region with low signal intensity (SI) on T2w MRI, high SI in the $b = 800$ DWI scan, low SI on the ADC map, and increased enhancement in the $K^{\text{trans}}$ and $k_{\text{ep}}$ maps. Tumor regions delineated on mp-MRI were compared with the delineations propagated from histopathology, and the distance and overlap were described. When overlapping, the distance and spatial overlap were quantified using the 95% Hausdorff distance between contours and the Dice coefficient. Delineated and pathological volumes were estimated using the T2w grid.

For LDR brachytherapy patients with seminal vesicle (SV) invasion, the visible tumor areas as well as a benign region were delineated but no distances with histopathology contours were determined.

**Statistics**

Significant differences ($p < 0.05$) of median imaging values between ROIs were tested with a non-parametric Friedman’s ANOVA. To further examine differences, a post hoc Wilcoxon signed rank test was used with a Bonferroni correction.

Using the EBRT patients, univariate and multivariate generalized linear mixed-effect modeling was applied to assess the predictive value of imaging on the voxel-wise likelihood of tumor. Voxels were grouped as follows: benign, resulting from a combination of unaffected PZ and CG for which H&E was available, and tumor, based on pathology delineations. To obtain the likelihood of tumor on a voxel level, fixed and random effects were included.

The T2w, ADC, $K^{\text{trans}}$, $k_{\text{ep}}$ maps, and voxel anatomical location (PZ or CG) were included as fixed effects. Random effects accounted for spatial clustering, by incorporating the voxel relative distance from the prostate center of mass and patient identifiers. When the association between model parameters and tumor probability was nonlinear, the parameters were grouped in quartiles and regression coefficients were
estimated for each group considering the first quartile as reference. The model fit was assessed using the Bayesian Information Criterion (BIC) (a decrease of 10 points reflects an improved fit) and by evaluating the residual random error. The contribution of predictors such as time since RT, use of hormonal therapy (HT), and treatment modality, included as fixed effects, was also investigated. A calibration curve was used to assess the quality of the best model. Analyses were performed in R (RStudio) using the lme4 package.

### Results

Thirteen patients had been primarily treated with EBRT and eight with LDR brachytherapy between 1999 and 2013. Median time between treatment and the MRI for recurrence diagnosis was 84 months for EBRT and 60 months for LDR brachytherapy. Following the D’Amico definition [16], 1, 8, and 12 patients had low-, intermediate-, and high-risk primary PCa. Eleven patients received HT as part of their primary treatment, but none received HT at the time of imaging. Patient characteristics can be found in Table 1. Gleason score was not assigned to the recurrent tumor as radiation-induced

| Table 1 Patient characteristics                  |
|-----------------------------------------------|
| Nadir PSA (ng/ml) [IQR]                         | 0.7 [0.9] |
| Median PSA level at MR imaging (ng/ml) [IQR]    | 5.4 [3.4] |
| Median time from MRI to SRP (months) [IQR]      | 3 [3] |
| Median iPSA level (ng/ml) [IQR]                 | 15 [22] |
| Primary clinical tumor stage                    |
| T1c                                           | 4 |
| T2a                                           | 4 |
| T2b                                           | 2 |
| T2c                                           | 1 |
| T3a                                           | 7 |
| T3b                                           | 3 |
| Primary Gleason grade                          |
| Gleason 6                                      | 6 |
| Gleason 7                                      | 10 |
| 7 (3 + 4)                                     | 3 |
| 7 (4 + 3)                                     | 3 |
| Gleason 8 (5 + 3)                              | 1 |
| Gleason 9 (5 + 4)                              | 1 |
| Recurrent pathological tumor stage             |
| pT2b                                          | 1 |
| pT2c                                          | 4 |
| pT3a                                          | 3 |
| pT3b                                          | 9 |
| pT3c                                          | 3 |

**IQR** interquartile range

---

**Fig. 1** Example of an EBRT patient. The white arrow points at the urethra, location used for the match of the H&E slide (b) with T2w MRI (a). The registered H&E slide (c) is placed side by side with the mp-MRI images where the prostate is delineated in white and the tumor in blue.
atypia can be a confounder for pathological interpretation [17].

**Pathological findings**

EBRT patients had an average tumor volume of 1.2 cm$^3$, LDR patients 0.51 cm$^3$. For all patients except one, recurrent tumor after LDR brachytherapy extended to the SV. In this subset, tumor within the gland was mainly small and sparse. For 2 patients, no tumor was visible in the available H&E slides, with their pathology reports describing tumors of small dimensions in the prostate apex, bladder neck, and/or extension to the SV. These patients were excluded from further analysis.

The average registration error for all slides was 1.1 ± 0.9 mm. Quantitative image analysis based on the matched H&E slides was performed for 19 patients and 56 slides (Fig. 1). Multifocal recurrent disease was present for all but one patient. Sixty-three percent of the tumors were located in the PZ and 11% in the CG. The remaining 26% covered both PZ and CG. Benign prostatic hyperplasia (BPH) could not be seen in the pathology slides matched to MRI. The pre-SRP biopsy report contained information about the location of positive cores for 17/21 patients. When compared to the SRP histopathology, biopsy correctly detected 42% of SV-located tumors, as well as 33% of left and 75% of right prostate gland tumors.

**Radiologists' delineations compared to histopathology**

Median delineated volumes (cm$^3$) were 0.34 (range, 0.04–2.14) for radiologist 1 and 0.56 (range, 0.06–3.50) for radiologist 2, and missed tumor foci were smaller than 1 and 0.5 cm$^3$, respectively.

---

Fig. 2  Example patients treated with primarily EBRT (a-c) and LDR brachytherapy (d) with histopathology delineations propagated to MRI (in blue) and tumor-suspected regions delineated by the experienced uro-radiologists (in yellow and red)
Radiologists’ contours did not visually overlap with pathology for 5 patients, with 3 of them missed by both. When overlapping with pathology, the median delineated volumes (cm\(^3\))—0.61 (range, 0.05–1.76) and 0.68 (range, 0.06–2.82)—slightly underestimated the corresponding median pathological tumor volumes (cm\(^3\))—0.74 (range, 0.01–2.82) and 0.74 (range, 0.02–2.82) (Fig. 2(A–C)). Contours overlapping with pathology had a median Dice coefficient of 0.64 (range, 0.1–0.8) and 0.58 (range, 0.01–0.83) and a median 95% Hausdorff distance (mm) of 3.6 (range, 0.4–20.9) and 6.2 (range, 0.9–17.1) for radiologists 1 and 2 respectively.

The pattern of recurrence after LDR brachytherapy, showing small and sparse foci (Fig. 2(D)), together with the artifacts caused by the seeds, made detection of recurrent tumor within the gland challenging. Disease extension to the SV was
more readily visible as it presented characteristic tumor features on MRI.

**MR imaging parameters**

Diffuse SI reduction throughout the prostate and a decreased conspicuity of zonal anatomy was observed on T2w. For most patients (10/17 with DCE), the PU region showed $K_{trans}$ enhancement without signs of malignancy (Fig. 1). Quantitative imaging values are reported for all ROIs in Fig. 3 for EBRT and Supplementary Fig. 1 for LDR brachytherapy patients. Further information about the values per ROI can be found in Supplementary Table 1.

**EBRT patients**

Friedman’s ANOVA test revealed significant differences between regions. A Wilcoxon signed rank test between tumor and PZ, with a corrected $\alpha = 0.05/6 = 0.008$, found median ADC (PZ = $1.3 \times 10^{-3}$ mm$^2$/s, tumor = $0.9 \times 10^{-3}$ mm$^2$/s), $K_{trans}$ (PZ = 0.13 min$^{-1}$, tumor = 0.23 min$^{-1}$), and $k_{ep}$ (PZ = 0.32 min$^{-1}$, tumor = 0.45 min$^{-1}$) to be significantly different. No imaging modality was significantly different between tumor and the CG. The PU region had the highest values for all but $k_{ep}$, with $K_{trans}$ (PU = 0.35 min$^{-1}$) and ADC (PU = $1.4 \times 10^{-3}$ mm$^2$/s) significantly higher than tumor. For T2w and $K_{trans}$, there was a considerable overlap between tumor and CG values (Fig. 3). The tumor had the lowest T2w and ADC and the highest $k_{ep}$ values.

**LDR brachytherapy patients**

For LDR brachytherapy patients, no significant differences were found between ROIs for all imaging modalities (Supplementary Fig. 1). The majority of the foci in the gland were small and did not have typical tumor characteristics on mp-MRI. The DWI was degraded due to the presence of the seeds (Fig. 4). Similarly to EBRT patients, the PU had the highest values for all but $k_{ep}$ maps. For the seven patients with SV invasion (Table 2), tumor in the SV had the highest values for $K_{trans}$ and $k_{ep}$ and lowest ADC and T2w values.

**Mixed modeling**

Univariately, all MRI parameters were significantly associated with tumor likelihood, $k_{ep}$ having the best statistical performance (BIC of 239,552, compared to 286,265, 247,260 and 254,273 for T2, ADC, and $K_{trans}$). Location (PZ = 0 or CG = 1) was the only non-imaging parameter that improved discrimination, with a voxel location in the CG decreasing tumor likelihood. A multivariate model combining all mp-MRI parameters and location obtained the best fit and was the most predictive for tumor (BIC of 198,942, $p < 0.001$) (Supplementary Table 2). A calibration curve for this model can be found in (Supplementary Fig. 2), showing that model predicted probabilities correspond well to the actual fractions of voxels with tumor in histopathology. Figure 5 shows an example of a reconstructed tumor probability map originating from the use of the mp-MRI model.

| Table 2 | Median imaging values for tumor and benign ROIs in the seminal vesicles for the LDR brachytherapy patients presented as median (Q10–Q90) |
|---|---|
| Imaging parameter | Seminal vesicles |
| | Tumor | Benign |
| T2w | Normalized T2 values (SI) | 2.9 (2.4–4.1) | 6.6 (4.2–8.4) |
| ADC ($\times 10^{-3}$ mm$^2$/s) | Median | 1.0 (0.9–1.9) | 1.7 (1.3–3.2) |
| DCE | $K_{trans}$ (min$^{-1}$) | Median | 0.20 (0.17–0.33) | 0.13 (0.06–0.22) |
| | $k_{ep}$ (min$^{-1}$) | Median | 0.59 (0.48–0.79) | 0.47 (0.29–0.55) |

Fig. 5  
**a** Tumor likelihood (with probabilities between 0 and 1) for every prostate voxel, obtained with the use of the multivariate mp-MRI model.  
**b** Region with probability values above 0.5 (red overlay on the T2w).  
**c** True pathological extent based on the matched H&E slide (yellow overlay on the T2w)
Discussion

In selected patients, focal salvage can achieve local control while reducing the risk of adverse events. An accurate representation of tumor location is necessary and mp-MRI has been used for this purpose [18–22]. In a quadrant analysis, T2w alone was reported to result in a similar tumor evaluation accuracy as in the pretreatment setting, but with substantial interobserver variability [23]. Benign confounders in previously irradiated prostates can complicate tumor detection. No consensus exists yet on the optimal MRI sequences for detecting local recurrence. Since patients only sporadically receive SRP after RT, and with limited availability of mp-MRI prior to surgery, studies reporting on these patients are usually based on small numbers [9, 23, 24]. Our study is unique in registering pathology to MRI to propagate high-resolution tumor delineations.

Consistent with literature, we found radio-recurrence disease to be often multifocal [25] yet with a different recurrence pattern in EBRT- and LDR brachytherapy-treated patients. No BPH was found in the available pathological slides, suggesting that it is not an imaging confounder as in the untreated prostate.

Our findings have implications for the design of focal salvage treatments. Smaller foci were often missed, and when overlapping with pathology, radiologists’ delineations often underestimated the real tumor size. Both radiologists performed quite similarly regarding the evaluated metrics. Our results are in line with findings in the de novo setting, comparing mp-MRI tumor detection to prostatectomy specimens: Borofsky et al [26] reported that in 26% of the patients, clinically important lesions were missed and in 8% there was substantial tumor size underestimation; according to Bratan et al [27], two observers underestimated tumor volume with every pulse sequence; and Steenbergen et al [28] described how teams of observers missed all small satellites and parts of the 18/22 correctly detected dominant lesions. In the setting of recurrent PCa, tumor volume underestimation in 1.5-T T2w MRI has been described using SRP samples [24]. The 95% Hausdorff distances reported here were above the 2.3 mm error observed in primary tumor delineations on mp-MRI [28]. Our results suggest a margin could improve index lesion coverage in focal salvage strategies. The development of MRI scoring and recurrent tumor delineation guidelines would likely improve consistency between observers and studies.

Analysis of the quantitative imaging maps showed that for EBRT patients, \( K_{\text{trans}} \), \( k_{\text{ep}} \), and ADC could successfully distinguish tumor in the PZ. Tumor detection in the CG was hampered by the presence of PU enhancement of \( K_{\text{trans}} \). Recurrent PCa after LDR brachytherapy was challenging to image due to the seeds, causing severe distortions in the DWI, and potentially unreliable ADC values. For these patients, no significant differences were found between ROIs, possibly due to the small sample size.

Using mixed modeling, the mp-MRI combination obtained the best performance in distinguishing tumor and benign tissue on a voxel level. Location significantly contributed to tumor likelihood, mimicking primary tumor prevalence maps in which the PZ has higher tumor incidence. The addition of DCE parameters improved tumor distinction. The decreased accuracy reported by Donati et al [12] may have been caused by the PU enhancement confounder.

The limited prostate coverage by the H&E slides made it impossible to reconstruct the overall shape of the gland, limiting registration accuracy between the slides and MRI. The main study limitation is the small sample size.

In conclusion, when using MRI to guide focal salvage treatments, all imaging modalities should be used for delineation, and the recommended treatment plan should encompass adequate margins beyond the visible tumor to accommodate for size underestimation. Tumor multifocality should also be accounted for. De-escalated whole-gland treatment with a focal tumor boost could potentially fulfill these requisites.

Funding This study has received funding by Dutch Cancer Society, grant number NKI 2013 – 5937.

Compliance with ethical standards

Guarantor The scientific guarantor of this publication is Uulke A. van der Heide, PhD.

Conflict of interest The authors declare that they have no conflict of interest.

Statistics and biometry One of the authors (Iris Walraven) has significant statistical expertise. Katarzyna Jozwiak, from the Netherlands Cancer Institute, has also provided valuable statistical advice.

Informed consent Written informed consent was waived by the Institutional Review Board.

Ethical approval Institutional Review Board approval was obtained.

Methodology

- Retrospective
- Observational
- Performed at one institution.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. Michalski J, Winter K, Roach M et al (2012) Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys 83: 363–370

2. Hruby G, Eade T, Kneebone A et al (2017) Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. Radiother Oncol 122:99–102

3. Bolla M, Tienhoven G, Warde P et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(10)70223-0

4. Duijzentkunst DA, Peters M, van der V oort van Zyp JR, Moerland MA, van Vulpen M (2016) Focal salvage therapy for local prostate cancer recurrences after primary radiation therapy: a comprehensive review. World J Urol 34:1521–1531

5. Rossof JS, Savage SJ, Prasad SM (2013) Salvage radical prostatectomy as management of locally recurrent prostate cancer: outcomes and complications. World J Urol 31:1347–1352

6. Perera M, Papa N, Christidis D et al (2017) Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937

7. Kollmeier MA, Zelefsky M, McBride S (2017) Magnetic resonance imaging-based salvage brachytherapy: moving toward a focal paradigm. Brachytherapy 16:770–777

8. Mazaheri Y, Vargas HA, Akin O et al (2012) Reducing the influence of b-value selection on diffusion-weighted imaging of the prostate: evaluation of a revised monoexponential model within a clinical setting. J Magn Reson Imaging 35:660–668

9. Pucar D, Shukla-Dave A, Hricak H et al (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 236: 545–553

10. Akin O, Gultekin DH, Vargas HA et al (2011) Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol 21:1970–1978

11. Zattoni F, Kawashima A, Morlacco A et al (2017) Detection of recurrent prostate cancer after primary radiation therapy: an evaluation of the role of multiparametric 3T magnetic resonance imaging with endorectal coil. Pract Radiat Oncol 7:42–49

12. Donati OF, Vargas HA, Gultekin DH, Hricak H (2013) Multiparametric prostate MR imaging with T2-weighted, diffusionweighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? Radiology 268:440–450

13. Abramowtiz MC, Li T, Buyyounouski MK et al (2008) The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 112:55–60

14. Myronenko A, Song X (2010) Point set registration: coherent point drift. IEEE Trans Pattern Anal Mach Intell 32:2262–2275

15. Puryasko AS, Rosenkrantz AB, Barentsz JO et al (2016) PI-RADS version 2: a pictorial update. Radiographics 36:1354–1372

16. D’Amico A, Whittington R, Malkowicz S, Al E (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974

17. Crook J, Malone S, Perry G et al (2000) Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 48:355–367

18. Ahmed HU, Cathcart P, McCartan N et al (2012) Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study. Cancer 118:4148–4155

19. Baco E, Gelet A, Crouzet S et al (2014) Hemi salvage high-intensity focused ultrasound (HIFU) in unilateral radiorecurrent prostate cancer: a prospective two-centre study. BJU Int 114:532–540

20. Hsu CC, Hsu H, Pickett B et al (2013) Feasibility of MR imaging/ MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys 85:370–377

21. Nguyen PL, Chen M-H, D’Amico AV et al (2007) Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 110:1485–1492

22. Peters M, Maenhout M, van der Voort van Zyp JRN et al (2014) Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life. Radiother Oncol 112:77–82

23. Sala E, Eberhardt SC, Akin O et al (2006) Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology 238:176–183

24. Pucar D, Hricak H, Shukla-Dave A et al (2007) Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 69:62–69

25. Jalloh M, Leapman MS, Cowan JE et al (2015) Patterns of local failure following radiation therapy for prostate cancer. J Urol. https://doi.org/10.1016/j.juro.2015.04.111

26. Borofsky S, George AK, Gaur S et al (2017) What are we missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. Radiology. https://doi.org/10.1148/radiol.2017152877

27. Bratan F, Melodelima C, Souchon R et al (2015) How accurate is multiparametric MR imaging in evaluation of prostate cancer volume? Radiology 275:144

28. Steenbergen P, Haustermans K, Lerut E et al (2015) Prostate tumor delineation using multiparametric magnetic resonance imaging: inter-observer variability and pathology validation. Radiother Oncol 115:186–190